PS
| |
Patient Square Capital LP13F | |
| Patient Square Capital LP | |
| Last update 2025-05-15 | 19 Stocks (4 new) |
| Value $242.00 Mil | Turnover 10 % |
Patient Square Capital LP Top Holdings of 2025-03-31
View Full List
| Ticker | | Company | Shares | Value ($1000) | Shares Change % | Weighting % | Trade Impact % | % of Shares outstanding | 3M Change % | YTD Change % | Market Cap $Mil | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ROIV | Roivant Sciences Ltd | 12,480,000 | 125,923.2 | 0% | 52.090 | 0% | 1.750 | +11.60% | -4.82% | 7,654.6 | Biotechnology | |
INSM | Insmed Inc | 330,250 | 25,194.8 | +7.51% | 10.420 | +0.73% | 0.180 | +31.92% | +45.77% | 19,116.7 | Biotechnology | |
LQDA | Liquidia Corp | 1,522,452 | 22,456.2 | -18.16% | 9.290 | -1.49% | 1.780 | -15.46% | +6.04% | 1,066.0 | Biotechnology | |
EYPT | EyePoint Pharmaceuticals Inc | 1,481,977 | 8,032.3 | +5.08% | 3.320 | +0.16% | 2.150 | +73.80% | +26.44% | 648.2 | Biotechnology | |
OCUL | Ocular Therapeutix Inc | 920,199 | 6,745.1 | +95.40% | 2.790 | +1.36% | 0.580 | +26.60% | +8.67% | 1,478.3 | Biotechnology | |
CGEM | Cullinan Therapeutics Inc | 878,897 | 6,653.3 | 0% | 2.750 | 0% | 1.490 | -0.53% | -38.18% | 444.4 | Biotechnology | |
NRIX | Nurix Therapeutics Inc | 447,296 | 5,313.9 | +0.22% | 2.200 | 0% | 0.590 | -4.12% | -39.54% | 868.3 | Biotechnology | |
MIRM | Mirum Pharmaceuticals Inc | 116,362 | 5,242.1 | +79.29% | 2.170 | +0.96% | 0.240 | +12.96% | +23.07% | 2,520.8 | Biotechnology | |
ELVN | Enliven Therapeutics Inc | 253,838 | 4,995.5 | +13.30% | 2.070 | +0.24% | 0.520 | +1.93% | -10.84% | 1,183.3 | Biotechnology | |
SRRK | Scholar Rock Holding Corp | 154,000 | 4,951.1 | +381.25% | 2.050 | +1.62% | 0.160 | +10.17% | -18.05% | 3,363.0 | Biotechnology |
Patient Square Capital LP's Historical Top Holdings Breakdowns
Patient Square Capital LP's Top Stock Picks
View Full List
| Ticker | | Company | Date | Action | Impact % | Price Range | Price | Price Change from Avrg% | Comment | Current Shares | Share Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ITCI Unlock Delisted | Intra-Cellular Therapies Inc | 2025-03-31 | Sold Out Sold Out | -2.25% | 81.78 ($124.62) 131.92 | $131.87 | 5.82% | Sold Out | 0 | -71,990 | |
GERN | Geron Corp | 2025-03-31 | Sold Out Sold Out | -1.75% | 1.59 ($2.44) 3.6 | $1.41 | -42.42% | Sold Out | 0 | -1,321,268 | |
SRRK | Scholar Rock Holding Corp | 2025-03-31 | Add Add | +1.62% | 32.15 ($38.47) 46.73 | $35.42 | -7.93% | Add 381.25% | 154,000 | 122,000 | |
KYMR | Kymera Therapeutics Inc | 2025-03-31 | New Buy New Buy | +1.61% | 27.37 ($36.45) 44.36 | $43.58 | 19.56% | New holding | 142,201 | 142,201 | |
LQDA | Liquidia Corp | 2025-03-31 | Reduce Reduce | -1.49% | 11.36 ($14.59) 16.52 | $12.47 | -14.53% | Reduce -18.16% | 1,522,452 | -337,919 | |
BPMC | Blueprint Medicines Corp | 2025-03-31 | New Buy New Buy | +1.41% | 86.69 ($97.55) 115.63 | $128.18 | 31.40% | New holding | 38,500 | 38,500 | |
OCUL | Ocular Therapeutix Inc | 2025-03-31 | Add Add | +1.36% | 5.93 ($7.69) 9.08 | $9.28 | 20.68% | Add 95.4% | 920,199 | 449,280 | |
SWTX | SpringWorks Therapeutics Inc | 2025-03-31 | Sold Out Sold Out | -1.26% | 32.5 ($46.03) 59.93 | $47.01 | 2.13% | Sold Out | 0 | -93,137 | |
MIRM | Mirum Pharmaceuticals Inc | 2025-03-31 | Add Add | +0.96% | 41.32 ($47.13) 53.16 | $50.89 | 7.98% | Add 79.29% | 116,362 | 51,462 | |
INSM | Insmed Inc | 2025-03-31 | Add Add | +0.73% | 65.25 ($76.49) 83.83 | $100.64 | 31.57% | Add 7.51% | 330,250 | 23,083 |
Patient Square Capital LP Total Holding History ($B)
Patient Square Capital LP's Asset Allocation
Patient Square Capital LP Past Portfolios
| Portfolio Date | Number of Stocks | New Stocks | Total Value ($Mil) | Q/Q Turnover |
|---|---|---|---|---|
Top Ranked Articles
- 1
Patient Square Capital LP's Hypothetical Growth since 2025-03-31
Patient Square Capital LP's Yearly Returns
| Year | Portfolio % | % | Excess Gain % |
|---|
Patient Square Capital LP's Holdings Heat Map
Size field:
Patient Square Capital LP's Holdings Bubble Chart
Patient Square Capital LP News
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers